WallStSmart

Lineage, Inc. Common Stock (LINE)vsSTAG Industrial Inc (STAG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 534% more annual revenue ($5.36B vs $845.18M). STAG leads profitability with a 32.4% profit margin vs -1.9%. STAG earns a higher WallStSmart Score of 64/100 (C+).

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81

STAG

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 7.0Value: 8.3Quality: 3.8
Piotroski: 4/9Altman Z: 0.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

STAGUndervalued (+42.2%)

Margin of Safety

+42.2%

Fair Value

$67.86

Current Price

$35.98

$31.88 discount

UndervaluedFair: $67.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

STAG4 strengths · Avg: 9.5/10
Profit MarginProfitability
32.4%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

EPS GrowthGrowth
57.9%10/10

Earnings expanding 57.9% YoY

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

STAG2 concerns · Avg: 2.5/10
Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Altman Z-ScoreHealth
0.702/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : STAG

The strongest argument for STAG centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 32.4% and operating margin at 37.8%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Bear Case : STAG

The primary concerns for STAG are Return on Equity, Altman Z-Score.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while STAG is a mature play — different risk/reward profiles.

STAG is growing revenue faster at 10.8% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

STAG scores higher overall (64/100 vs 36/100), backed by strong 32.4% margins and 10.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

STAG Industrial Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant industrial properties throughout the United States.

Want to dig deeper into these stocks?